ISAL 2023 | The current role of CPX-351 in AML and clinical trials evaluating this agent
Thomas Cluzeau, MD, PhD, University Hospital of Nice, Nice, France, discusses current clinical indications for the use of CPX-351 in acute myeloid leukemia (AML), and highlights ongoing trials evaluating this agent. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So today, as you know, the CPX351 is recommended for patients with AML-MRC and therapy-related AML. But based on the first results, we would like to increase the indication of CPX-351 based on the good safety of the drug, less GI toxicity, less skin toxicity and maybe a more deep CR after using CPX-351. So today there are some clinical trials ongoing evaluating CPX-351 in patients, excluding patients in the label...
So today, as you know, the CPX351 is recommended for patients with AML-MRC and therapy-related AML. But based on the first results, we would like to increase the indication of CPX-351 based on the good safety of the drug, less GI toxicity, less skin toxicity and maybe a more deep CR after using CPX-351. So today there are some clinical trials ongoing evaluating CPX-351 in patients, excluding patients in the label. So for patients with intermediate ELN prognostic, for example, and we try to evaluate the level of MRD after CPX-351. So there is a German clinical trial ongoing and there is also a French clinical trial, the ALFA2101, open in France to evaluate this drug in this setting.
Read more...
Disclosures
Jazz, Astellas, Arog, Novartis
